192.81
Schlusskurs vom Vortag:
$189.57
Offen:
$188.06
24-Stunden-Volumen:
893.07K
Relative Volume:
0.73
Marktkapitalisierung:
$26.46B
Einnahmen:
$1.96B
Nettoeinkommen (Verlust:
$-253.24M
KGV:
-101.41
EPS:
-1.9012
Netto-Cashflow:
$94.06M
1W Leistung:
+2.55%
1M Leistung:
+18.22%
6M Leistung:
+24.48%
1J Leistung:
+54.57%
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Vergleichen Sie NTRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
NTRA
Natera Inc
|
192.81 | 26.02B | 1.96B | -253.24M | 94.06M | -1.9012 |
|
TMO
Thermo Fisher Scientific Inc
|
558.31 | 210.57B | 43.74B | 6.59B | 6.11B | 17.30 |
|
DHR
Danaher Corp
|
214.01 | 153.21B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
627.66 | 50.75B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
143.20 | 41.35B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
217.83 | 37.15B | 15.70B | 1.24B | 2.01B | 6.9036 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Natera, known for spotting cancer recurrence, wades into early detection - statnews.com
Can momentum traders help lift Natera Inc.2025 Investor Takeaways & Expert Approved Momentum Ideas - newser.com
Is Natera Inc. stock positioned well for digital economy2025 Top Decliners & AI Based Buy and Sell Signals - newser.com
Natera reports progress in blood test for precancerous polyp detection By Investing.com - Investing.com South Africa
Natera (NTRA) Advances in Blood-Based CRC Screening with Promisi - GuruFocus
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity - BioSpace
Key resistance and support levels for Natera Inc.2025 Earnings Surprises & Daily Stock Trend Reports - newser.com
Natera reports progress in blood test for precancerous polyp detection - Investing.com
Does Signatera’s Positive Phase 3 Data Shift the Long-Term Growth Story for Natera (NTRA)? - Yahoo Finance
Price momentum metrics for Natera Inc. explainedQuarterly Profit Summary & Smart Money Movement Alerts - newser.com
How Recent Developments Are Reshaping the Natera Investment Story - Yahoo! Finance UK
How high can Natera Inc. stock go2025 Bull vs Bear & High Return Trade Opportunity Guides - newser.com
Ranking Natera Inc. among high performing stocks via toolsTrade Entry Summary & Safe Entry Point Identification - newser.com
Automated trading signals detected on Natera Inc.Earnings Beat & Reliable Price Breakout Signals - newser.com
Regression analysis insights on Natera Inc. performanceWeekly Profit Report & Consistent Return Strategy Ideas - newser.com
Will Natera Inc. stock outperform Nasdaq indexJuly 2025 Update & Real-Time Chart Pattern Alerts - newser.com
What analysts say about Natera Inc stockTrade Execution Strategies & Today’s Picks, Tomorrow’s Winners - earlytimes.in
Natera Inc.’s New Prenatal Test Study: A Potential Game-Changer in Genetic Screening - TipRanks
Natera’s New Study: A Potential Game-Changer in Breast Cancer Treatment - TipRanks
Using portfolio simulators with Natera Inc. includedTake Profit & Real-Time Chart Pattern Alerts - newser.com
Why Natera Inc. stock could see breakout soonRecession Risk & AI Forecast Swing Trade Picks - newser.com
Natera’s FIND-CRC Study: A Potential Game-Changer in Colorectal Cancer Screening - TipRanks
Natera Inc.’s Innovative Approach to Heart Transplant Rejection Monitoring: A Study Update - TipRanks
Natera’s PROCEED-CRC Study: A Step Forward in Early Cancer Detection - TipRanks
How Investors May Respond To Natera (NTRA) Signatera Data Boosting FDA Case in Bladder Cancer - simplywall.st
November 2026 Options Now Available For Natera (NTRA) - Nasdaq
Published on: 2025-10-27 06:35:18 - newser.com
Published on: 2025-10-27 05:35:59 - newser.com
Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights - Bluefield Daily Telegraph
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Natera Inc-Aktie (NTRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
Oct 22 '25 |
Sale |
186.68 |
920 |
171,746 |
69,189 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
Oct 24 '25 |
Sale |
196.77 |
755 |
148,561 |
69,189 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
Oct 23 '25 |
Sale |
187.16 |
495 |
92,644 |
69,944 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):